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A pilot study was conducted in an endemic village for bancroftian filariasis to find out the
compliance and antifilarial action of large doses of mebendazole (30 mg/kg/day). Thirty
eight patients with early clinical filariasis and 16 with asymptomatic microfilaraemia
were treated, under supervision. ‘The compliance for drug consumption was high and
there were no serious adverse reactions.Majority of the side effects were gastrointestinal
and mild. The drug, in combination with diethylcarbamazine (DEC), showed microfilari-
cidal effect, but the effect was similar to that seen with DEC alone.In s many as 5 of
the 13, who were followed at 1 yr, microfilaria persisted at the end of 1 yr, though with a
reduced density. Prolonged (1 yr) treatment with mebendazole in combination with DEC
did not have a beneficial effect in most patients with clinical disease.
Diethylcarbamazine (DEC) has been the
drug of choice in the treatment of filariasis
for nearly four decades1,2. In the past
decade, several new compounds have been
tried and found to possess antifilarial acti-
vity3-6. One of them, mebendazole, an
antihelmenthic, has been shown to have some
microfilaricidal action7-9, but, in view of its
poor enteric absorption10, it needs to be given
in large doses.In such larger doses, patient
compliance was found to be lower due to
gastrointestinal side effects7-9.
A pilot study was conducted to find out the
compliance and possible adverse reactions
associated with large doses of mebendazole
and to develop the methodology and tools
for conducting a field trial. This paper
reports the findings on compliance, adverse
r actio s and antifilarial activity of meben-
dazole.
Material & Methods
Study population : The pilot study was
community based and conducted in 1983-85
in the village Thomur, Chingleput district,
Tamil Nadu, endemic for Wuchereria
bancrofti. In all, 54 patients, in the age
group 15-64 yr, were admitted into the study.
Care was taken to exclude pregnant women
in view of the possible teratogenic effect of
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mebendazole11. Sixteen patients had asymp-
tomatic microfilaraemia and 38 patients had
clinical filariasis, which included 3 patients of
acute lymphadenopathy, 15 of chronic
genital disease (9 having hydrocele), 12 of
lymphoedema of limbs and 8 patients with
both genital and limb disease. However,
patients with elephantiasis of genitals or limbs
were not included. The age and sex distri-
bution of the study population is shown in
Table I, separately for the microfilaraemic and
clinical filariasis groups.
Regimen used: Earlier observations had
suggested that repeated courses of DEC for
a prolonged duration would be beneficial in
clinical filariasis12,13, and that mebendazole
was a new promising microfilaricidal com-
pound7-9. Therefore, as a pilot experiment,
patients with clinical filariasis were given
DEC (6 mg/kg) and mebendazole (30 mg/kg)
daily for 12 days (intensive phase) and weekly
for 1 yr (continuation phase). Mf carriers
were given 12 days of intensive treatment
only. Seven of them were treated with
mebendazole and DEC and the other 9
with DEC alone. Individuals with acute
episodes, during the followup phase, were
Table I. Age and sex distribution of the study
population
Age-group Mf group Disease group
(yr)
Males Females Males Females
15-24 6 4 12 2
25-34 – 1 5 2
35-44 – – 9 5
45-54 1 3  – 2
55-64 – 1 1  –
Total 7 9 27 11
treated with mebendazole and DEC for
12 d ys.
Procedures : In a clinic set up in the village,
the prescribed chemotherapy was administered
under direct supervision of trained field staff.
A comprehensive, precoded clinical form was
developed to record the details of clinical
examination, by a physician. All patients
ere examined at intake, at the end of inten-
sive phase and at 6, 12 and 24 months.All
clinical assessments were made without the
knowledge of the earlier results. Also, 1 m
of blood was obtained, by venepuncture after
2200 h, at all the above time points, except at
24 months, and examined for mf by mem-
brane filtration technique (MFC)14. In
addition, weekly surveillance was maintained
during the first year for symptoms of adverse
reactions, non-compliance or acute filarial
attacks.
Results & Discussion
Compliance : Among the 38 patients in the
clinical disease group, in 2 patients treatment
was stopped for medical reasons (one each
with peptic ulcer and severe vomiting) and
one patient defaulted.Of the remaining 35,
31 (89%) consumed more than 80 per cent
of the prescribed chemotherapy in spite of
the very heavy dose (12-20 tablets at a time)
of mebendazole,while the remaining 4
consumed less than 80 per cent of the prescri-
bed chemotherapy.In both the clinical
disease and mf groups, compliance for night
blood specimens by venepuncture was also
high (193 specimens collected of the required
208).
Adverse reactions : In spite of the large daily
dose of mebendazole (1200-2000 mg), in only
one patient with clinical filariasis, vomiting
was severe and necessitated termination of
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mebendazole. Ten (26%) of the 38 patients
with clinical filariasis and 6 (38 %) of the 16
patients with mf had mild side effects which
were mainly gastrointestinal and subsided in
a few days with symptomatic treatment.
Similar findings have been reported by other
investigators using mebendazole7,8. In these
studies, the drug was used in a lower dosage
(6 mg/kg), in contrast to the present study
(30 mg/kg). However, it should be noted
that reports, based on animal experiments,
indicate that mebendazole may have some
teratogenic effect11.
Acute attacks : During the one year of
intensive surveillance, 10 attacks of acute
filariasis were treated; 8 (21%) of the 38 in
the disease group and 2 (13 %) of the 15 in the
mf group. This difference was not statis-
tically significant.Of the patients with acute
atta ks in the mf group, one each belonged to
th  two regimens.
Post treatment status : Mf group : At the
end of the intensive phase, 6 of the 9 patients
treated with DEC were positive for mf,
although with a reduced density, while only
one of the 6 patients treated with meben-
dazole + DEC was found to be positive
(Table II). But this difference was not
maintained at 6 months and 1 yr. Two of
4 patients in the mebendazole + DEC group
and 3 of 9 in the DEC group were still mf
positive at the end of 1 yr. Thus, although
based on small numbers, the data in Table II
Table II. Status of microfilaraemics before and after treatment
Patient
no.
1
2
3
4
5
6
Age
19
16
16
33
46
18
Sex mf density (using MFC technique) at
intake end of Rx 6 months 1 yr
Mebendazole+DEC*:
M > 1000 0 Absent 40
F 978† 0 0 Ref
F 825 3 11 Left
F 231 0 13 2
F 78 0 0 0
M 5 0 0 0
DEC alone :
1 57 F > 1000
2 15 M 900
3 23 F 532
4 23 M 286†
5 15 F 153
6 48 F 90
7 54 M 5
8 15 M 2
9 52 F 2
*one patient who died due to snake bite, excluded
†patient developed acute attack and was retreated
4 8 4
4 9 5
8 0 0
0 0 0
6 0 0
4 0 0
7 0 8
0 0 0
0 0 0
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suggest that the treatment, whether meben-
dazole + DEC or DEC alone, had micro-
filaricidal effect, both in terms of rate of
clearance and density, and that this effect
was similar for the two regimens. It was
also seen that 4 of the 5 patients in whom mf
persisted at 1 yr had high pretreatment mf
counts. The persistence of mf, though with
markedly reduced density, in as many as 5
(38 %) of the 13 patients, who were followed
at 1 yr, could be due to the partial effect of
the drug, at least in a proportion of patients,
on the adult filarial worms3,4,15. Similar
findings on the microfilaricidal action of
mebendazole have been reported earlier7,8.
Disease group: Out of the 38 patients treated,
in 2 patients treatment was stopped for
medical reasons, 1 defaulted and 2 were
absent for the examination at 2 yr. The
pretreatment clinical status in the remaining
33 patients is shown in Table III as also that
at the end of 2 yr.Of these 33, 30 patients
had completed 80 per cent or more of the
chemotherapy prescribed. In 30 patients
evidence of clinical filarias was still seen at
th  end of 2 yr, in spite of prolonged treatment
using mebendazole in combination with DEC.
In 3 female patients, all with filarial oedema,
the disease disappeared at the end of 2 yr.
All the 38 patients in the disease group
were mf negative at the start of the study.
Blood samples were collected in 37 and 29 of
them at 6 months and 1 yr respectively.All
the specimens were negative for mf except for
1 patient (with 1 mf) at 1 yr.
In conclusion, the pilot experience suggested
that (i) mebendazole in large doses along with
DEC had no serious side effects, (ii) the
microfilaricidal effect of mebendazole + DEC
was similar to that seen with DEC alone,
althou h based on small numbers, and (iii)
prolonged treatment with mebendazole in
combination with DEC did not have a
Table III. Status of clinical disease before and after chemotherapy
Initial disease status Total Disease status at the end of 2 yr
patients
No. (a) (b) (c) (d) (e)
Disease
(a) Acute lymphadenopathy 3 – 3 – – – –
(b) Chronic inflammation of 4 – 2* – – 1 1
cord and/or testes
(c) Hydrocele 8 – 2* 1 3* – 2
(d) Lymphoedema of limbs 11 3 1 – – 7 –
(e) Both genital and limb 7 – – 1 2 – 4
disease
Total 33 3 8 2 5 8 7
*Three patients received < 80 per cent of the prescribed chemotherapy
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beneficial effect in most patients with clinicalSoutheast Asian J Trop Med Public Health 9
filariasis. (1978) 571.
8. Chantin, M.M. and Laigret, J. Effect of single-.
dose of mebendazole on microfilaria of 50 carriers
of W. bancrofti var pacific microfilaria. Bull
Soc Pathol Exot 68 (1975) 198.
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